The role of CCND1 alterations during the progression of cutaneous malignant melanoma
暂无分享,去创建一个
R. Ádány | T. Kiss | G. Emri | Viktória Lázár | Róza Ádány | Viktória Koroknai | M. Balázs | Tímea Kiss | Viktória Lázár | Gabriella Emri | Laura Vízkeleti | Szilvia Ecsedi | Zsuzsa Rákosy | Adrienn Orosz | Viktória Koroknai | Margit Balázs | Szilvia Ecsedi | Z. Rákosy | L. Vízkeleti | Adrienn Orosz | Viktoria Koroknai
[1] R. Assoian,et al. Transcriptional regulation of the cyclin D1 gene at a glance , 2008, Journal of Cell Science.
[2] Thomas D. Schmittgen,et al. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.
[3] T. Godfrey,et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. , 2000, Cancer research.
[4] A. Wojas-Pelc,et al. Cyclin D1 and D3 expression in melanocytic skin lesions , 2010, Archives of Dermatological Research.
[5] J. Guitart,et al. Homogeneous Staining Regions for Cyclin D1, a Marker of Poor Prognosis in Malignant Melanoma , 2012, The American Journal of dermatopathology.
[6] M. Malumbres,et al. MicroRNAs and the cell cycle. , 2011, Biochimica et biophysica acta.
[7] R. Ádány,et al. Chromosomal imbalances in laryngeal and hypopharyngeal cancers detected by comparative genomic hybridization , 2005, Cytometry. Part A : the journal of the International Society for Analytical Cytology.
[8] Richard A Scolyer,et al. Histologically ambiguous ("borderline") primary cutaneous melanocytic tumors: approaches to patient management including the roles of molecular testing and sentinel lymph node biopsy. , 2010, Archives of pathology & laboratory medicine.
[9] A. Lueking,et al. Determination and validation of off-target activities of anti-CD44 variant 6 antibodies using protein biochips and tissue microarrays. , 2008, BioTechniques.
[10] Chenguang Wang,et al. Cyclin D1/cyclin-dependent kinase 4 interacts with filamin A and affects the migration and invasion potential of breast cancer cells. , 2010, Cancer research.
[11] R. Assoian,et al. Integrin-dependent signal transduction regulating cyclin D1 expression and G1 phase cell cycle progression , 2005, Cancer and Metastasis Reviews.
[12] L. Morrison,et al. Fluorescence In Situ Hybridization (FISH) as an Ancillary Diagnostic Tool in the Diagnosis of Melanoma , 2009, The American journal of surgical pathology.
[13] T. Golub,et al. A Mechanism of Cyclin D1 Action Encoded in the Patterns of Gene Expression in Human Cancer , 2003, Cell.
[14] Xiaolong Yang,et al. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. , 2010, The American journal of pathology.
[15] K. Nagashima,et al. Cyclin D1, p16 and retinoblastoma gene product expression as a predictor for prognosis in non-small cell lung cancer at stages I and II. , 2001, Lung cancer.
[16] R. Ádány,et al. Prognostic relevance of the expressions of CAV1 and TES genes on 7q31 in melanoma. , 2012, Frontiers in bioscience.
[17] Jeffrey E Gershenwald,et al. Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] G. C. Nogueira,et al. Stages I and II , 2000 .
[19] Hong Wu,et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E–mutated melanomas , 2008, Molecular Cancer Therapeutics.
[20] R. Sutherland,et al. Cyclin D1 and mammary carcinoma: new insights from transgenic mouse models , 2001, Breast Cancer Research.
[21] Andrew R. Green,et al. CCND1 amplification and cyclin D1 expression in breast cancer and their relation with proteomic subgroups and patient outcome , 2008, Breast Cancer Research and Treatment.
[22] K. Nathanson. Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma. , 2010, Biochemical pharmacology.
[23] T. Saida,et al. Specific dermoscopy patterns and amplifications of the cyclin D1 gene to define histopathologically unrecognizable early lesions of acral melanoma in situ. , 2005, Archives of dermatology.
[24] Bruno Augusto Benevenuto Andrade,et al. Immunohistochemical Expression of p16, p21, p27 and Cyclin D1 in Oral Nevi and Melanoma , 2012, Head and Neck Pathology.
[25] R. Ádány,et al. EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis , 2007, International journal of cancer.
[26] S Detre,et al. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. , 1995, Journal of clinical pathology.
[27] A. Cochran,et al. Molecular classification of melanomas and nevi using gene expression microarray signatures and formalin-fixed and paraffin-embedded tissue , 2009, Modern Pathology.
[28] B. Thiers. Distribution and Significance of Occult Intraepidermal Tumor Cells Surrounding Primary Melanoma , 2009 .
[29] Y. Moroi,et al. Expression of c-Kit, p-ERK and cyclin D1 in malignant melanoma: an immunohistochemical study and analysis of prognostic value. , 2011, Journal of dermatological science.
[30] R. Ádány,et al. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization , 2012, Melanoma research.
[31] M. Imoto,et al. Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression , 2007, Cancer science.
[32] J. Diehl,et al. Nuclear cyclin D1: An oncogenic driver in human cancer , 2009, Journal of cellular physiology.
[33] S. Steinberg,et al. Expression levels of eIF4E, VEGF, and cyclin D1, and correlation of eIF4E with VEGF and cyclin D1 in multi-tumor tissue microarray. , 2007, Oncology reports.
[34] D. Pinkel,et al. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. , 1998, Cancer research.
[35] R. Ádány,et al. Characterization of candidate gene copy number alterations in the 11q13 region along with BRAF and NRAS mutations in human melanoma , 2009, Modern Pathology.
[36] Yi Tie,et al. MicroRNA-193b regulates proliferation, migration and invasion in human hepatocellular carcinoma cells. , 2010, European journal of cancer.
[37] Chenguang Wang,et al. Minireview: Cyclin D1: normal and abnormal functions. , 2004, Endocrinology.
[38] E. Schuuring,et al. Expression of cyclin D1 and EMS1 in bladder tumours; relationship with chromosome 11q13 amplification. , 1996, Oncogene.
[39] G. Nai,et al. Role of ROC1 protein in the control of cyclin D1 protein expression in skin melanomas. , 2011, Pathology, research and practice.
[40] A. Rademaker,et al. Copy number gains in 11q13 and 8q24 [corrected] are highly linked to prognosis in cutaneous malignant melanoma. , 2011, The Journal of molecular diagnostics : JMD.
[41] D. Pinkel,et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. , 2002, Cancer research.
[42] M. Strauss,et al. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. , 1995, Cancer research.
[43] D. Schadendorf,et al. Somatic alterations in the melanoma genome: A high‐resolution array‐based comparative genomic hybridization study , 2010, Genes, chromosomes & cancer.
[44] J. Stockman,et al. Distinct Sets of Genetic Alterations in Melanoma , 2007 .
[45] Chen Kai-hu. Application of fluorescence in situ hybridization , 2012 .